SCHEMBL3373906

SCHEMBL3373906

CCOC(=O)C(Cc1ccc(OCCc2nc(-c3ccc(OC)c(OC)c3)sc2C)c(OC)c1)OCC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
TP53 P04637 3/20 0.43
LMNA P02545 2/20 0.43
THRB P10828 1/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DCK P27707 2/20 0.42
PPARA Q07869 5/20 0.42
PPARD Q03181 2/20 0.42
PPARG P37231 4/20 0.41
KDR P35968 5/20 0.40
EGFR P00533 1/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3371628 0.93 PPARG (0.47) MAPTTP53LMNATHRBDCK
SCHEMBL3375387 0.92 PPARA (0.40) PPARAPPARDPPARGKDR
SCHEMBL3371149 0.91 PPARA (0.40) MAPTTP53LMNATHRBPPARA
SCHEMBL3372687 0.87 PPARG (0.46) PPARAPPARDPPARG
SCHEMBL3374096 0.86 PPARA (0.42) MAPTTP53LMNATHRBDCK
SCHEMBL3374198 0.85 PPARG (0.45) MAPTPPARAPPARDPPARG
SCHEMBL3369112 0.85 PPARG (0.46) PPARAPPARDPPARG
SCHEMBL3370909 0.84 PPARG (0.47) PPARAPPARDPPARG
SCHEMBL3374070 0.83 PPARA (0.39) MAPTTP53LMNATHRBKDM4E
SCHEMBL3374173 0.83 PPARG (0.46) PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR MAPT 4327/4885TP53 4393/4885LMNA 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.